Thread by @NavroopSingh_

Covaxin doses 86% effective against symptomatic reinfections in health workers: AIIMS study theprint.in/health/covaxin…

The research looked at reinfection rates among 4,978 healthcare workers, who had tested positive for SARS-CoV-2 infection between 3 March 2020 and 18 June 2021 during peak of 2nd wave of Delta.

The research team, that included AIIMS director Randeep Guleria, identified 124 cases of reinfection, which is 2.5 per cent of the study group.

SARS-CoV-2 Reinfection Rate and Estimated Effectiveness of the Inactivated Whole Virion Vaccine BBV152 Against Reinfection Among Health Care Workers in New Delhi, India jamanetwork.com/journals/jaman…

Rate of Reinfections in HCWs 15,244, 4978 got reinfected which is 32.7% of total age group !

Any Reinfections:

Unvaccinated - 60 of 472 (18.05%)
One Shot - 39 of 356 (15.62%)
Fully Vaxed - 17 of 1080 (2.18%)

Symptomatic Reinfections:

Unvaxed - 50 of 472 (15.04%)
One Shot - 31 of 356 (12.42%)
Fully Vaxed - 13 of 1089 (1.67%)

Asymptomatic Reinfections:

Unvaxed - 10 of 472 (3.01%)
Partially Vaxed - 8 of 356 (6.41%)
Fully Vaxed - 4 of 1089 (0.51%)

The estimated effectiveness of BBV152 (COVAXIN ) against reinfection was 86% (95% CI, 77%-92%); symptomatic reinfection, 87% (95% CI, 76%-93%); and asymptomatic reinfection, 84% (95% CI, 47%-95%) among fully vaccinated HCWs.

The inactivated vaccine BBV152 appears to offer a high protective effect of 86% in fully vaccinated HCWs against reinfection.

The study generates evidence to vaccinate fully with both the doses, even in HCWs who were previously infected to combat the continuous threat of future surges of SARS-CoV-2 and related variants of concern.